Mike Firth
AstraZeneca (United Kingdom)(GB)AstraZeneca (Australia)(AU)
Publications by Year
Research Areas
CRISPR and Genetic Engineering, RNA regulation and disease, Advanced biosensing and bioanalysis techniques, Pluripotent Stem Cells Research, RNA Interference and Gene Delivery
Most-Cited Works
- → Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis(2007)365 cited
- → In vivo CRISPR editing with no detectable genome-wide off-target mutations(2018)319 cited
- → Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity(2017)150 cited
- → Engineered Cas9 extracellular vesicles as a novel gene editing tool(2022)110 cited
- → Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing(2023)109 cited
- → BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B(2018)97 cited
- → CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs(2020)76 cited
- → Systematic Evaluation of CRISPRa and CRISPRi Modalities Enables Development of a Multiplexed, Orthogonal Gene Activation and Repression System(2019)52 cited
- → Customizable virus-like particles deliver CRISPR–Cas9 ribonucleoprotein for effective ocular neovascular and Huntington’s disease gene therapy(2025)50 cited
- → Universal toxin-based selection for precise genome engineering in human cells(2021)49 cited